Venture Capital: Genesis Therapeutics Closes $200M Round To Expand AI-Powered Drug Discovery

Genesis Therapeutics is a Stanford University spin-off.

Genesis Therapeutics, an AI drug discovery company, has secured a $200 million Series B funding round to advance its AI-powered drug development pipeline into clinical testing. Founded in 2019 as a spinoff from Stanford University, Genesis focuses on utilizing its deep learning platform called GEMS to design small-molecule drug compounds and predict their interactions with the body, particularly with flexible or challenging proteins.

This funding round, which was oversubscribed, is a significant increase from its previous $52 million Series A funding in 2020. Existing investors, including Rock Springs Capital, T. Rowe Price Associates, Menlo Ventures, Radical Ventures, and Andreessen Horowitz, as well as new investors like a16z Bio + Health, Fidelity Management & Research Company, BlackRock, and Nvidia’s VC arm, NVentures, participated in this round. (Fierce Biotech)

Genesis plans to leverage the new capital to propel its AI-enabled programs into clinical testing and expand its drug discovery efforts. The company’s GEMS platform is known for generating novel molecules, predicting properties, and targeting previously challenging protein structures.

“GEMS is uniquely capable of identifying and enabling drug candidates for challenging, data-poor, and previously undruggable targets, thereby allowing Genesis to make progress towards breakthrough treatments with the potential for transformative impact across significant and underserved patient populations,” Genesis said in a statement.

Founded by Professor Vijay Pande from Stanford University, Genesis is led by CEO Evan Feinberg and has collaborations with Genentech and Eli Lilly.

Related Story:  Atomic AI Closes $35M Series ‘A’ For RNA Drug Discovery

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…